January 16, 2024 7:18am

Investors began the year selling or taking “some” profits; there are opportunities to add “some” exposure

Pre-open Indications: 1 Sell into Strength, 2 Positive and 3 Negative Indications

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What RMi provides is a trusted source of share pricing intelligence.

Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progression.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Tuesday: The pre-open Dow futures are DOWN -0.31% or (-119 points), the S&P futures are DOWN -0.39% or (-18 points) as the Nasdaq futures are DOWN -0.48% (-82 points)

Stock futures are slipping on Tuesday,

European stocks executed a negative start

Asia-Pacific markets drooped.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies … https://www.regmedinvestors.com/articles/13283

US markets were closed Monday in observation of Martin Luther King Jr. Day,

Friday, the Dow lost 118.04 points, or 0.31%, to close at 37,592.98, the S&P 500 ended +3.59 points or 0.08% higher at 4,783.83, and the Nasdaq Composite closed just above barely +2.58 points or +0.02% at 14,972.76.

Economic Data Docket: Wednesday's retail sales data should serve as the main calendar catalysts.

  • Retail sales are expected to rise 0.4% in December, an increase from the 0.3% gain in November, as US consumers continue to power a surprisingly durable economic expansion.
  • Retail sales’ numbers could fuel recessionary fears and concerns about economic growth if U.S. consumer spending sees a cooldown.
  • Coming week, Thursday's initial jobless claims data and a look at consumer sentiment from the University of Michigan out Friday will warrant a close look from investors.

 

Friday, RegMed Investors (RMi) Closing Bell: “a Friday’s opening jive followed by afternoon dive after 3-other weekly downfalls; as momentum rocks and then rolls-over in the cell and gene therapy fragmented sector.” … https://www.regmedinvestors.com/articles/13285

 

Q1/24: 2 holidays, 6 negative and 3 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Friday, Thursday’s, Wednesday and last Tuesday Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed down -$0.48 after Thursday’s -$0.65, Wednesday’s -$0.88, last Tuesday’s +$0.10 and the previous Monday’s +$1.79 with a positive +$0.17 or +0.66% pre-open indication.

Sage Therapeutics (SAGE) closed down -$0.34 after Thursday’s +$1.49, Wednesday’s -$0.97, last Tuesday’s +$1.27 and the previous Monday’s +$3.63 with a positive +$0.53 or +2% pre-open indication

 

Negative Indications:

Friday, Thursday’s, Wednesday and last Tuesday Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$1.69 after Thursday’s -$1.53, Wednesday’s -$1.59, last Tuesday’s +$1.37 and the previous Monday’s +$7.45 with a negative -$0.39 or -0.20% pre-open indication.

Ionis Pharmaceuticals (IONS) closed down -$0.01 after Thursday’s +$1.34, Wednesday’s -$0.67, last Tuesday’s +$0.56 and the previous Monday’s +$1.62 with a negative -$0.54 or -1.01% pre-open indication

Intellia Therapeutics (NTLA) closed down -$0.48 after Thursday’s -$0.73, Wednesday’s -$0.41, last Tuesday’s -$0.78 and the previous Monday’s +$1.44 with a negative -$0.31 or -1.12% pre-open indication

 

Sell-into-Strength Indication:

Friday, Thursday’s, Wednesday and last Tuesday Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Vericel (VCEL) closed up +$0.85 after Thursday’s +$0.06 with a positive +$0.02 or +0.05% pre-open indication.

 

The BOTTOM LINE: it’s now the 3nd week of 2024, we have eaten more value that even almost exceeded the last months of 2023.

  • (1/12) Friday closed negative with 13 incliners, 21 decliners and 1 flat
  • Thursday closed negative with 8 incliners, 26 decliners and 1 flat
  • Wednesday closed negative with 14 incliners, 21 decliners and 0 flat
  • Tuesday closed negative with 14 incliners, 18 decliners and 3 flats
  • (1/8) Monday closed positive with 28 incliners, 6 decliners and 1 flat

It was a tough start in 2024 as the cell and gene therapy sector as the JPM healthcare conference fizzles to an end.

  • (1/5) Friday closed negative with 12 incliners, 23 decliners and 0 flat
  • Thursday closed positive with 22 incliners, 12 decliners and 1 flat
  • Wednesday closed negative with 6 incliners, 29 decliners and 0 flat
  • (1/2) Tuesday closed positive with 21 incliners, 14 decliners and 0 flat

Coming attractions …Q4 and FY23 reporting season and “runways” will get measured as consensus and estimates will get missed!

For the next few weeks, if you're buying on weakness, you might be jumping onto a sinking ship even as … Q4 and FY23 earnings LPS (loss-per-share) are due even though some highlights were delivered to facilitate JPM presentations – there are consensus and beaten estimates to be reckoned!

News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

  • It's also a good idea to take some profits, especially if you didn't do so in past sessions. <IBD>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.